Abstract
The courses of six patients with adenosine deaminase (ADA) and two with purine nucleoside phosphorylase (PNP) deficiencies were evaluated before and after therapy. The heterogeneity of immunologic and clinical parameters was striking in each enzyme deficiency. In both PNP and ADA deficiency, some patients had very low immunoglobulin levels, while others had normal levels. T-cell function was always low in patients with ADA deficiency. In the two patients with PNP deficiency, contrary to the classical descriptions of this disorder, T-cell function fluctuated with time. Five ADA-deficient patients were treated with irradiated normal red-cell transfusions as a form of enzyme replacement and showed no lasting benefit. Three of the ADA-deficient patients and one of the PNP-deficient patients were given transplants of haploidentical parental bone marrow stem cells without pretransplant immunosuppression. In the PNP-deficient patient, chimerism has not been documented on enzymatic testing. One ADA-deficient patient has demonstrated long-term engraftment with good B-and T-cell function. Haploidentical bone marrow transplantation is currently the preferred therapy for enzyme-deficient patients with absent T-cell function who do not have an HLA-identical donor, as it may result in a lasting reconstitution of immune function. In those patients with unsatisfactory responses to transplantation, however, specific enzyme replacement or gene therapy may be considered in the future.
Similar content being viewed by others
References
Bortin MM, Rimm AA: Severe combined immunodeficiency disease: Characterization of the disease and results of transplantation. JAMA 238:591–600, 1977
Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067–1069, 1972
Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK: Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1:1010–1013, 1975
Kredich NM, Hershfield MS: Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency.In The Metabolic Basis of Inherited Disease, JB Stanbury, JB Wyngaarden, DS Fredrickson, JL Goldstein, MS Brown (eds). New York, McGraw-Hill, 1983, pp 1157–1183
Hirschhorn R, Ratech H: Metabolic basis of immunodeficiency disorders.In Primary Immunodeficiencies, INSERM No. 16 Symposium, M Seligmann, WH Hitzig, (eds). Amsterdam, Elsevier/North-Holland, 1980, pp 237–250
Ammann AJ: Immunological aberrations in purine nucleoside phosphorylase deficiencies. CIBA Found Symp 68:55–75, 1978
Bruyn CHMM: Inherited purine enzyme deficiencies: Prenatal and heterozygote detection. Clin Biochem 16:38–42, 1983
Buckley RH, Dees SC, O'Fallon WM: Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy. Pediatrics 41:600–611, 1968
Buckley RH, Dees SC: Serum immunoglobulins. III. Abnormalities associated with chronic urticaria in children. J Allergy 40:294–303, 1968
Schiff RI, Buckley RH, Gilbertsen RB, Metzgar RS: Membrane receptors and in vitro lymphocyte responsiveness in immunodeficiency. J Immunol 112:376–386, 1974
Haynes BF: Human T lymphocyte antigens as defined by monoclonal antibodies. Immunol Rev 57:127–161, 1981
Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G: Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor function. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 130:2133–2141, 1983
Phillips JH, Babcock GF: NKP-15: A monoclonal antibody reactive against purified human natural killer cells and granulocytes. Immunol Lett 6:143–149, 1983
Wedgwood RJ, Ochs D, Davis SD: The recognition and classification of immunodeficiency diseases with bacteriophage φX174. Birth Defects Orig Art Ser 11:331–338, 1975
Snyder FF, Mendelsohn J, Seegmiller JE: Adenosine metabolism in phytohemagglutinin stimulated lymphocytes. J Clin Invest 58:654–666, 1976
Fox IH, Andres CM, Gelfand EW, Biggar D: Purine nucleoside phosphorylase deficiency: Altered kinetic properties of a mutant enzyme. Science 197:1084–1086, 1977
Polmar SH, Wetzler EM, Stern RC, Hirschhorn R: Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet 2:743–746, 1976
Polmar SH, Stern RC, Schwartz AL, Wetzler EM, Chase PA, Hirschhorn R: Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med 295:1337–1343, 1976
Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, van Wauwe J: A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 203:1309–1310, 1979
Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O'Reilly RJ: Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61:341–348, 1983
Buckley RH, Schiff SE, Sampson HA, Schiff RI, Markert ML, Knutsen AP, Lawton AF, Hershfield MS, Huang AT, Mickey GH, Ward FE: Development of immunity in severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 136:2398–2407, 1986
van der Weyden MB, Buckley RH, Kelley WN: Molecular form of adenosine deaminase in severe combined immunodeficiency. Biochem Biophys Res Commun 57:590–595, 1974
Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, Abuchowski A: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). N Engl J Med 316:589–596, 1987
Hirschhorn R, Roegner V, Jenkins T, Seaman C, Piomelli S, Borkowsky W: Erythrocyte adenosine deaminase deficiency without immunodeficiency. J Clin Invest 64:1130–1139, 1979
Zegers BJM, Stoop JW, Staal GEJ, Wadman SK: An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient. CIBA Found Symp 68:231–253, 1978
Staal GEJ, Stoop JW, Zegers BJM, van Heukelom LHS, van der Vlist MJM, Wadman SK, Martin DW: Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes. J Clin Invest 65:103–108, 1980
Rich KC, Mejias E, Fox IH: Purine nucleoside phosphorylase deficiency: Improved metabolic and immunologic function with erythrocyte transfusions. N Engl J Med 303:973–977, 1980
Aiuti F, Businco L, Fiorilli M, Galli E, Quinti I, LeMoli S, Seminara R, Goldstein G: Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies. Birth Defects Orig Art Ser 19:267–272, 1983
Ammann AJ, Wara DW, Allen T: Immunotherapy and immunopathologic studies in a patient with nucleoside phosphorylase deficiency. Clin Immunol Immunopathol 10:262–269, 1978
Markert ML, Buckley RH: Natural-killer-cell function and bone marrow transplantation. N Engl J Med 315:1418–1419, 1986
Fischer A, Friedrich W, Levinsky R, Vossen J, Griscelli C, Kubanek B, Morgan G, Wagemaker G, Landais P: Bonemarrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968–1985. Lancet 2:1080–1084, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Markert, M.L., Hershfield, M.S., Schiff, R.I. et al. Adenosine deaminase and purine nucleoside phosphorylase deficiencies: Evaluation of therapeutic interventions in eight patients. J Clin Immunol 7, 389–399 (1987). https://doi.org/10.1007/BF00917017
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00917017